Literature DB >> 17413000

Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer.

Stephen N Birrell1, Lisa M Butler, Jonathan M Harris, Grant Buchanan, Wayne D Tilley.   

Abstract

There is now considerable evidence that using a combination of synthetic progestins and estrogens in hormone replacement therapy (HRT) increases the risk of breast cancer compared with estrogen alone. Furthermore, the World Health Organization has recently cited combination contraceptives, which contain synthetic progestins, as potentially carcinogenic to humans, particularly for increased breast cancer risk. Given the above observations and the current trend toward progestin-only contraception, it is important that we have a comprehensive understanding of how progestins act in the millions of women worldwide who regularly take these medications. While synthetic progestins, such as medroxyprogesterone acetate (MPA), which are currently used in both HRT and oral contraceptives were designed to act exclusively through the progesterone receptor, it is clear from both clinical and experimental settings that their effects may be mediated, in part, by binding to the androgen receptor (AR). Disruption of androgen action by synthetic progestins may have serious deleterious side effects in the breast, where the balance between estrogen signaling and androgen signaling plays a critical role in breast homeostasis. Here, we review the role of androgen signaling in the normal breast and in breast cancer and present new data demonstrating that androgen receptor function can be perturbed by low doses of MPA, similar to doses achieved in serum of women taking HRT. We propose that the observed excess of breast malignancies associated with combined HRT may be explained, in part, by synthetic progestins such as MPA acting as endocrine disruptors to negate the protective effects of androgen signaling in the breast. Understanding the role of androgen signaling in the breast and how this is modulated by synthetic progestins is necessary to determine how combined HRT alters breast cancer risk, and to inform the development of optimal preventive and treatment strategies for this disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17413000     DOI: 10.1096/fj.06-7518com

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  30 in total

1.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

Review 2.  Integration of progesterone receptor action with rapid signaling events in breast cancer models.

Authors:  Carol A Lange
Journal:  J Steroid Biochem Mol Biol       Date:  2007-09-14       Impact factor: 4.292

Review 3.  Anchoring junctions as drug targets: role in contraceptive development.

Authors:  Dolores D Mruk; Bruno Silvestrini; C Yan Cheng
Journal:  Pharmacol Rev       Date:  2008-05-15       Impact factor: 25.468

Review 4.  Role of the androgen receptor in triple-negative breast cancer.

Authors:  Murtuza Rampurwala; Kari B Wisinski; Ruth O'Regan
Journal:  Clin Adv Hematol Oncol       Date:  2016-03

5.  Corepressor effect on androgen receptor activity varies with the length of the CAG encoded polyglutamine repeat and is dependent on receptor/corepressor ratio in prostate cancer cells.

Authors:  Grant Buchanan; Eleanor F Need; Jeffrey M Barrett; Tina Bianco-Miotto; Vanessa C Thompson; Lisa M Butler; Villis R Marshall; Wayne D Tilley; Gerhard A Coetzee
Journal:  Mol Cell Endocrinol       Date:  2011-06-01       Impact factor: 4.102

Review 6.  Deciphering the divergent roles of progestogens in breast cancer.

Authors:  Jason S Carroll; Theresa E Hickey; Gerard A Tarulli; Michael Williams; Wayne D Tilley
Journal:  Nat Rev Cancer       Date:  2016-11-25       Impact factor: 60.716

Review 7.  Breast and prostate cancer: more similar than different.

Authors:  Gail P Risbridger; Ian D Davis; Stephen N Birrell; Wayne D Tilley
Journal:  Nat Rev Cancer       Date:  2010-02-11       Impact factor: 60.716

8.  Cinical Significance of Androgen Receptor, CK-5/6, KI-67 and Molecular Subtypes in Breast Cancer.

Authors:  Münire Kayahan; Ufuk Oğuz İdiz; Zuhal Gucin; Fazilet Erözgen; Naim Memmi; Mahmut Müslümanoğlu
Journal:  J Breast Health       Date:  2014-10-01

Review 9.  Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?

Authors:  T E Hickey; J L L Robinson; J S Carroll; W D Tilley
Journal:  Mol Endocrinol       Date:  2012-06-28

10.  Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance).

Authors:  Debra L Barton; Lynne T Shuster; Travis Dockter; Pamela J Atherton; Jacqueline Thielen; Stephen N Birrell; Richa Sood; Patricia Griffin; Shelby A Terstriep; Bassam Mattar; Jacqueline M Lafky; Charles L Loprinzi
Journal:  Support Care Cancer       Date:  2017-11-21       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.